Activating mutations in ALK provide a therapeutic target in neuroblastoma.
George RE, Sanda T, Hanna M, Fröhling S, Luther W 2nd, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT.
George RE, et al. Among authors: mcgrady p.
Nature. 2008 Oct 16;455(7215):975-8. doi: 10.1038/nature07397.
Nature. 2008.
PMID: 18923525
Free PMC article.